Skip to main content

Table 3 Change of treatment in men initially prescribed an α-blocker plus an antimuscarinic combination treatment and non-persistent at 12 months

From: A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands

  FDC Concomitant therapy
Change of treatment in men non-persistent at 12 months, N (%) N = 324 N = 859
 Switcha 19 (5.9) 56 (6.5)
 No switch/discontinuationb 305 (94.1) 803 (93.5)
Switched to, N (%) N = 19 N = 56
 Combination with new α-blocker 1 (5.3) 5 (8.9)
 Combination with new antimuscarinic 6 (31.6) 25 (44.6)
 Concomitant therapy with the same drugs 9 (47.4) 3 (5.4)
 Concomitant therapy with a new α-blocker and antimuscarinic 3 (15.8) 0
 FDC 0 23 (41.1)
No switch/discontinuation, N (%) N = 305 N = 803
 α-blocker therapy only 58 (19.0) 246 (30.6)
 Antimuscarinic therapy only 19 (6.2) 107 (13.3)
 No therapy changes 228 (74.8) 450 (56.0)
  1. FDC fixed-dose combination
  2. aAlternative combination therapy prescribed within 30 days following discontinuation of index combination therapy
  3. bNo alternative combination therapy prescribed within 30 days following discontinuation of index combination therapy